Prescription drug · ANDA
Irinotecan Hydrochloride NDC 0143-9701
Irinotecan hydrochloride 20 mg/mL · Injection · Intravenous · Hikma Pharmaceuticals USA Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0143-9701-01 | 0014397010100143970101 | 5 mL in 1 VIAL, GLASS (0143-9701-01)Marketed from Dec 20, 2010 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Irinotecan Hydrochloride
- Generic name (nonproprietary)
- irinotecan hydrochloride
- Active ingredients
- Irinotecan hydrochloride — 20 mg/mL
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- Hikma Pharmaceuticals USA Inc.NDC labeler code 0143
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 091032
- Marketing start
- Listing expires
- Other FDA classes
- Topoisomerase Inhibitors (Mechanism)
- Identifiers
- Product ID 0143-9701_204eb37a-642f-4321-9466-414c32a6bbceSPL ID 204eb37a-642f-4321-9466-414c32a6bbceSPL set ID be716692-6b4f-47b6-83d1-01665861626bRxCUI 1726319, 1726324UNII 042LAQ1IISUPC 0301439701019
- Pharmacologic class
- Topoisomerase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N400143970101followed by a unit qualifier and the quantityPackage 00143-9701-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Irinotecan Hydrochloride Injection, USP is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan Hydrochloride Injection, USP is a topoisomerase inhibitor indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
Excerpt only. Read the full label for complete information.
About NDC 0143-9701
- What is NDC 0143-9701?
- 0143-9701 is the product NDC for Irinotecan Hydrochloride, Irinotecan hydrochloride 20 mg/mL injection, listed with the FDA by Hikma Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Irinotecan Hydrochloride.
- What is the active ingredient?
- Irinotecan hydrochloride.
- Who is the labeler?
- Hikma Pharmaceuticals USA Inc., NDC labeler code 0143. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Irinotecan Hydrochloride?
- 19 other product NDCs are listed under this name. See all Irinotecan Hydrochloride NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Irinotecan Hydrochloride products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Apotex Corp. | 60505-6272 | 60505-6272-01 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Eugia US LLC | 55150-355 | 55150-0355-01 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Northstar Rx LLC | 16714-027 | 16714-0027-01 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Northstar Rx LLC | 16714-131 | 16714-0131-01 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Eugia US LLC | 55150-352 | 55150-0352-01 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Eugia US LLC | 55150-353 | 55150-0353-01 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Eugia US LLC | 55150-354 | 55150-0354-01 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Gland Pharma Limited | 68083-382 | 68083-0382-01 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Xiromed LLC | 70700-170 | 70700-0170-22 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Apotex Corp. | 60505-6128 | 60505-6128-0060505-6128-01 |
Other NDCs under ANDA 091032
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9583 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9702 |